These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 19913170

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
    Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M.
    Cancer Res; 2003 Jan 01; 63(1):86-92. PubMed ID: 12517782
    [Abstract] [Full Text] [Related]

  • 5. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
    Di Paolo D, Pastorino F, Zuccari G, Caffa I, Loi M, Marimpietri D, Brignole C, Perri P, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M, Pagnan G.
    J Control Release; 2013 Sep 28; 170(3):445-51. PubMed ID: 23792118
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
    Corti A, Ponzoni M.
    Ann N Y Acad Sci; 2004 Dec 28; 1028():104-12. PubMed ID: 15650236
    [Abstract] [Full Text] [Related]

  • 8. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M.
    Ann N Y Acad Sci; 2004 Dec 28; 1028():90-103. PubMed ID: 15650235
    [Abstract] [Full Text] [Related]

  • 9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 28; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 10. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM, Mumbengegwi DR, Charrois GJ.
    Clin Cancer Res; 2005 May 01; 11(9):3567-73. PubMed ID: 15867261
    [Abstract] [Full Text] [Related]

  • 11. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
    Nam SM, Kim HS, Ahn WS, Park YS.
    Oncol Res; 1999 May 01; 11(1):9-16. PubMed ID: 10451027
    [Abstract] [Full Text] [Related]

  • 12. The liposomal formulation of doxorubicin.
    Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB.
    Methods Enzymol; 2005 May 01; 391():71-97. PubMed ID: 15721375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.
    Clin Cancer Res; 2008 Nov 15; 14(22):7320-9. PubMed ID: 19010847
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M.
    Cancer Res; 2006 Oct 15; 66(20):10073-82. PubMed ID: 17047071
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts.
    Ponthan F, Lindskog M, Karnehed N, Castro J, Kogner P.
    Oncol Rep; 2003 Oct 15; 10(5):1587-92. PubMed ID: 12883745
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.
    Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB.
    Cancer Res; 2000 Dec 15; 60(24):6942-9. PubMed ID: 11156394
    [Abstract] [Full Text] [Related]

  • 20. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
    Zuccari G, Milelli A, Pastorino F, Loi M, Petretto A, Parise A, Marchetti C, Minarini A, Cilli M, Emionite L, Di Paolo D, Brignole C, Piaggio F, Perri P, Tumiatti V, Pistoia V, Pagnan G, Ponzoni M.
    J Control Release; 2015 Aug 10; 211():44-52. PubMed ID: 26031842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.